Nurix Therapeutics, Inc. NRIX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -439.3%-99.1pp | -340.2%-20.8pp | -319.3%-58.6pp | -260.8%+148pp | -408.9%-18.3pp | |
| Net margin | -411.4%-96.5pp | -314.9%-22.4pp | -292.5%-57.9pp | -234.6%+135pp | -369.4%-14.5pp | |
| Returns | ||||||
| Return on equity | -61.4%-11.8pp | -49.6%+15.7pp | -65.4%-14.7pp | -50.7%+13.5pp | -64.2%-10.9pp | |
| Return on invested capital | -70.2%+2.0pp | -72.2%+9.6pp | -81.8%-15.6pp | -66.2%+13.6pp | -79.8%-11.1pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0.2×0.0× | 0.2×0.0× | 0.1×0.0× | |
| Liquidity | ||||||
| Current ratio | 6×-1.0× | 7×+1.7× | 5.4×-1.5× | 6.8×+0.6× | 6.3×-0.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.2×0.0× | 0.1×+0.1× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $4.37-29.7% | $6.22+40.5% | $4.42-17.1% | $5.34-7.3% | $5.76-26.7% | |
| Valuation | ||||||
| Market capitalization | $1.64B-8.4% | $1.79B+151% | $714.04M-4.1% | $744.82M-36.5% | $1.17B-27.1% | |
| Price / sales | 22.9×+1.5× | 21.3×+12.8× | 8.5×+0.1× | 8.4×-12.4× | 20.8×-8.7× | |
| Price / book | 3.4×+0.1× | 3.3×+1.4× | 1.9×+0.3× | 1.7×-0.8× | 2.4×-0.6× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Nurix Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Nurix Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
